Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
Pfizer (Australia) LIGNOCAINE HYDROCHLORIDE 1% (50 mg/5 mL) injection BP ampoule, Bridgewest Perth Pharma Pty Ltd, CON-1137
Product name
Pfizer (Australia) LIGNOCAINE HYDROCHLORIDE 1% (50 mg/5 mL) injection BP ampoule
Sponsor name
Bridgewest Perth Pharma Pty Ltd
Consent start
Consent no.
CON-1137
Standard
Paragraph 10(4) (c), Paragraph 10(4) (d), Paragraph 10(4) (f), Paragraph 10(4) (k), Subparagraph 10(15) (b) (vi), of Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines
Non-compliance with standard
The product(s) have print direct stamped onto the plastic ampoules (TECA print)
and do not comply with the requirements of TGO 91 as described in the
attachment. This is due to the ampoule labels being physically unable to
encompass all requirements as prescribed by TGO 91 due to limited available
printable area.
Therapeutic product type
Prescription medicines